Drugs / dazukibart
dazukibart
English name Dazukibart
also known as
PF-06823859
Monoclonal antibody targets IFNB1 via inhibition
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05257798 | Feb 2022 → Mar 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05037409 | Sep 2021 → Mar 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT05879718 | Jul 2023 → Jun 2025 | cutaneous lupus erythematosus, systemic lupus erythematosus | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05192200 | Dec 2021 → Nov 2023 | dermatomyositis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03181893 | Jan 2018 → May 2022 | dermatomyositis | Pfizer | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT06698796 | Jan 2025 → Nov 2027 expected | dermatomyositis | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05895786 | May 2023 → Jul 2027 expected | myositis disease | Pfizer | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02766621 Comparator | May 2016 → Aug 2017 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dazukibart | “The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM).” NCT05895786 ↗2“12-week treatment with dazukibart, an anti-IFNβ monoclonal antibody, reduced disease activity in moderate-to-severe DM.” PMID 42273013 ↗ Jun 2026 |
| Known as | PF-06823859 | “PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection” NCT05257798 ↗ |
| Action | Inhibit | “supporting IFNβ inhibition as a highly promising therapeutic strategy” PMID 39798982 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “PF-06823859, an anti-interferon β monoclonal antibody” PMID 33352008 ↗ Dec 2020 |
| Route | Intravenous | “intravenous PF-06823859” PMID 33352008 ↗ Dec 2020 |
| Target | IFNB1 | “a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ” PMID 39798982 ↗ Jan 2025 |